Company Overview of FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically-driven diseases. The company’s drug discovery engine deploys screening and structure-based approaches across various families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. It has a strategic partnership with Celgene Corporation. FORMA Therapeutics, Inc. was formerly known as Forma Pharmaceuticals, Inc. and changed its name to FORMA Therapeutics, Inc. in February 2008. The company was incorporated in 2007 and is based in Watertown, Massachusetts and has additional chemistry operations in Branford, Connecticut. FORMA Therapeutics, Inc. operat...
500 Arsenal Street
Watertown, MA 02472
Founded in 2007
Key Executives for FORMA Therapeutics, Inc.
Co-Founder, Chief Executive Officer, President and Director
Head of Biomolecular Screening and Executive Director
Compensation as of Fiscal Year 2015.
FORMA Therapeutics, Inc. Key Developments
Forma Therapeutics Appoints John Hohneker, M.D., as Executive Vice President, Head of Research and Development
Jul 22 15
FORMA Therapeutics announced the appointment of John Hohneker, M.D., as Executive Vice President and Head of Research and Development. Most recently he served as Senior Vice President and Global Head of Development for the immunology and dermatology franchise at Novartis Pharmaceuticals Corporation. Dr. Hohneker will be responsible for leading all aspects of the Company’s discovery and development efforts. Previously he also served as Senior Vice President of U.S. Oncology Clinical Development and Medical Affairs where he played a key role in the development, approval, and/or commercialization of several important life-changing products such as Gleevec®, Tasigna®, Zometa®, Afinitor®, and Exjade®.
FORMA Therapeutics, Inc. Presents at Boston CEO Conference, May-26-2015 through May-27-2015
Apr 16 15
FORMA Therapeutics, Inc. Presents at Boston CEO Conference, May-26-2015 through May-27-2015. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Presentation Date & Speakers: May-26-2015, Steven Tregay, Co-Founder, Chief Executive Officer, President and Director. May-27-2015, Steven Tregay, Co-Founder, Chief Executive Officer, President and Director.
FORMA Therapeutics, Inc. Appoints Paolo Paoletti as a Board of Directors
Apr 13 15
FORMA Therapeutics announced the appointment of Paolo Paoletti as a Board of Directors. In addition to serving as a director, Dr. Paoletti will also lead FORMA’s Research & Development Committee as its chairperson; in this capacity, his strategic clinical and research insights will be applied to FORMA’s target family drug discovery paradigm. Dr. Paoletti held several executive leadership roles in oncology at GSK, including Head of Oncology R&D Unit, Member of the Executive Board for Portfolio Investment and Chairman of the Oncology Portfolio Board. In his global leadership roles, he maintained the accountability for GSK’s entire oncology business and was responsible for drug discovery from target identification through registration, including product life cycle management and commercial strategy.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|